Pleasure for Food and Endocannabinoids in Obesity

Obesity Clinical Trial

— PLOBEC  

Official title:

A New Method for the Characterisation of Pleasure for Food in Obesity and Relationships With the Endocannabinoid System

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01985139
• Other study ID #: C13-33
• Secondary ID: 2013-A00982-43
• Status: Recruiting
• Phase: N/A
• First received: November 4, 2013
• Last updated: February 23, 2016
• Start date: January 2014
• Est. completion date: February 2016

Study information

• Verified date: February 2016
• Source: Institut National de la Santé Et de la Recherche Médicale, France
• Contact: Bruno Aouizerate, professor
• Phone: 05 57 57 37 06
• Email: bruno.aouizerate[@]u-bordeaux2.fr
• Is FDA regulated: No
• Health authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé
• Study type: Interventional

Clinical Trial Summary

Disturbances in hedonic and motivational processes play a major role in the pathophysiology of obesity. To date, experimental approaches for the study of emotional and motivational processing rely on subjective assessment scales. We have therefore developed two novel computer-generated tasks challenging respectively visual and temporal discrimination capacities for a quantitative and objective measurement of the hedonic and motivational state in humans. According to the task, the subjects are asked to view and to compare two stimuli, an appetitive one (food pictures) and its devalued counterpart (food pictures in greyscale), at each trial, assessing either the size (task A) or the duration of presentation (task B). From these considerations, the present project aims at using our novel tool to: i) assess the hedonic and motivational state in subjects with obesity, ii) compare their responses with healthy volunteers, and iii) establish relationships with biological markers known to be highly involved in the regulation of both emotional and motivational processes, such as endocannabinoids. The present project should demonstrate that the behavioral tests validated in our laboratory are relevant experimental tools for the diagnostic/clinical assessment and for the phenotypic characterization of obese patients. The application of the test in the therapeutic context could add further information about the efficacy and relevance of the chosen therapy. Finally, our project will provide information on the biological substrates of hedonic and motivational impairments that might become target of therapy in obesity.

Description:

Disturbances in hedonic and motivational processes play a major role in the pathophysiology of reward-related diseases, such as obesity. To date, experimental approaches for the study of emotional and motivational processing rely on subjective assessment scales. We have therefore developed and validated a novel computer-generated test challenging visual and temporal discrimination capacities in humans. The subjects are asked to view and to compare two stimuli, an appetitive one (food pictures; F) and its devalued counterpart (food pictures in greyscale; D), at each trial, assessing either the size (task A) or the duration of presentation (task B). Geometric figures are used as controls and presented in color (C) or greyscale (D). Both tasks are registered under the French agency for the protection of computer software. Here, we propose to use our novel test to: i) assess the hedonic and motivational state in subjects suffering from obesity, ii) compare their responses with healthy volunteers, and iii) establish relationships with biological markers known to be highly involved in the regulation of both emotional and motivational processes, such as endocannabinoids. Responses to the test in obese patients will be evaluated during two separate experimental sessions under either fasting or satiety conditions.

The present study is expected to begin mid-November 2013 for a total duration of 24 consecutive months. A sample of 25 patients suffering from obesity will be recruited and compared with 25 healthy normal volunteers who are free from any previous or current metabolic and psychiatric disorders. They will be matched on age and sex. They will be screened using the "Association pour la Méthodologie et la Documentation en Psychiatrie" questionnaire for obtaining a series of information, comprising the marital status, number of children, number of siblings, education and training, professional qualifications, significant life events… They will be evaluated with the Mini-International Neuropsychiatric Interview in order to determine the presence of mood disorders and associated psychopathology. The Three-Factor Eating Questionnaire will be employed for measuring three separate aspects of eating behavior: cognitive restraint, uncontrolled eating, and emotional eating. This will be completed with the Multidimensional Body Self-Relations Questionnaire and the State-Trait Anxiety Inventory in order to assess the body satisfaction and anxiety levels, respectively. Beyond all these assessments, two separate experimental sessions will be conducted, one in satiety and the other in fasting. During each session, the participants will be asked to perform the two validated instrumental tasks in front the screen of a computer. Plasma levels of endocannabinoids will be monitered by collecting blood samples prior to the consumption of a calorically-defined meal and while carrying out the computer-generated tasks under satiety. Blood will be withdrawn at the same time-points during the session in fasting. Visual analogue scales (VAS) assessing hunger levels will be completed before blood is collected. A VAS will be also used for the global assessment of appetitive properties of the viewed food images just before the end of the second experimental session.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: February 2016
• Est. primary completion date: February 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

Obese patients :

1. Be between 18 and 60 year-old

2. Have a body mass index ranging from 35 to 50 kg/m2

3. Have no previous history of surgical treatment of obesity

4. Have received no standard intervention for obesity within the last 3 months before study

5. Have a stable weight (variation <5%) within the last 3 months before study

6. Have a restriction score <9 on the three-factor eating questionnaire

7. Be free from any current and previous psychiatric disorder, such as major depression or drug abuse/dependence

8. Understand and accept the design and constraints of the present study

9. Be a beneficiary or member of health insurance plan

10. Provide written consent to the study after receiving clear information

Healthy volunteers :

1. Be between 18 and 60 year-old

2. Be free from any current and previous psychiatric disorder, such as major depression or drug abuse/dependence

3. Understand and accept the design and constraints of the present study

4. Be a beneficiary or member of health insurance plan

5. Provide written consent to the study after receiving clear information

Exclusion Criteria:

Obese patients :

1. Suffer from monogenic obesity

2. Take any psychotropic treatment such as anxiolytic/hypnotic drugs over the last week preceding the study

3. Be a pregnant or nursing woman

4. Use alcohol over the last two days preceding the study

Healthy volunteers :

1. Suffer from any current and previous somatic or psychiatric condition

2. Have a body mass index below 18,5 kg/m2 or above 25 kg/m2

3. Take any psychotropic treatment such as anxiolytic/hypnotic drugs over the last week preceding the study

4. Be a pregnant or nursing woman

5. Use alcohol over the last two days preceding the study

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening

Related Conditions & MeSH terms

• Obesity

Intervention

Behavioral:
• Computer-based tasks
Computer-based tasks designed to assess size and time discrimination capacities

Biological:
• Blood sampling
Blood drawn for the measurement of circulating endocannabinoids concentrations

Locations

Country	Name	City	State
France	Neurocentre Magendie (INSERM U862)	Bordeaux

Sponsors (1)

Lead Sponsor	Collaborator
Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the Point of subjective equality (PSE)	The PSE is defined as the ratio "F"/"D" or "C"/"D" for which the stimulus "F" or "C" was judged greater than "D" with a probability of 0.5	From fasting to satiety conditions 3 days apart (days 4 and 7 after inclusion)	No
Secondary	Change in the Percentage of subjective discrimination (PSD)	The PSD is defined as the percentage of responses where the stimulus "F" or "C" was judged greater than "D" during the trials where the stimulus "F" or "C" was physically equal to "D", in terms of size or duration of presentation.	From fasting to satiety conditions 3 days apart (days 4 and 7 after inclusion)	No
Secondary	Circulating endocannabinoids concentrations		Determined on blood samples collected during the experimental sessions under fasting and satiety (days 4 and 7 after inclusion)	No